Open access data will soon require business models, says Deepak Singh at bbgm. And he's not the only one to believe this, as he points out several posts that speak to putting open data into a useable (and accessible) framework as being key to building upon it. The best way to do this, of course, is to set up a business and charge a fee. Re-iterates Singh, "Data, especially open data, needs to be accompanied by APIs that allow the data to be accessed in a number of formats.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.